[go: up one dir, main page]

WO2011051289A1 - Active ingredient product - Google Patents

Active ingredient product Download PDF

Info

Publication number
WO2011051289A1
WO2011051289A1 PCT/EP2010/066170 EP2010066170W WO2011051289A1 WO 2011051289 A1 WO2011051289 A1 WO 2011051289A1 EP 2010066170 W EP2010066170 W EP 2010066170W WO 2011051289 A1 WO2011051289 A1 WO 2011051289A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
active substance
active ingredient
active
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/066170
Other languages
German (de)
French (fr)
Inventor
Bilgi Uz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATUREMED AS
Original Assignee
NATUREMED AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATUREMED AS filed Critical NATUREMED AS
Publication of WO2011051289A1 publication Critical patent/WO2011051289A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a drug preparation for external
  • the present invention relates to the use of the active substance preparation for the preparation of a preparation suitable for the treatment of humans, in particular for the treatment of diabetes.
  • the object of the present invention is to provide an active substance preparation based on herbal active ingredients which is particularly suitable for use in people suffering from diabetes.
  • the present invention has the features of claim 1 or 7.
  • amino acids from a group of amino acids comprising methionine, methyl aspartic acid and methyl glutamic acid.
  • the active substance preparation is used as solution and / or con- Serving agent has an alcohol which is preferably selected from a group of alcohols which comprises cetyl alcohol, ceteareth-25, ceteareth-6 and stearyl alcohol.
  • the active substance preparation is prepared on the basis of a water / oil emulsion having a vegetable thickening agent.
  • the adhesion of the active substance preparation at a selected body site is increased, on the other hand this increase in viscosity is achieved without synthetic additives having to be added.
  • the drug preparation may comprise at least one additive from a group of additives comprising glycerol, paraffin liquid, glyceryl stearate (Wo llwachs) or dimethycones (silicone).
  • glycerol paraffin liquid
  • glyceryl stearate Wo llwachs
  • dimethycones sicone
  • a recipe for the active substance preparation has proved to be particularly suitable for practical use and has versatile applicability, which is shown in the table below with the individual formulation components listed. - Lawsonia Inermis 16.60%
  • Henna meal (Lawsonia Inermis) is used as thickening center in the embodiment listed explicitly in terms of its composition.
  • Advantageous active ingredients and active ingredient catalysts amino acids
  • additional ingredients used such as benzophenone-4, which acts as a sunscreen, an application of the active compound preparation under direct sunlight, as outside closed rooms, allows without A negative influence of the drug combination by UV radiation would be feared.
  • the example formulation contains additional adjuvants as constituents, such as, for example, potassium chloride (potash) and various salts.
  • preservative additives such as, for example, propylparaben or methylchloroisothiazolinone, may also be added to it.
  • the complementary addition of antiseptic ingredients may prove beneficial. As Jesto ff or to set the desired
  • Concentration of the drug preparation the remainder of the total mass of the drug preparation consists essentially of water.
  • the Wirksto ffgarparat invention is particularly suitable in the case of the above-described recipe example for application to the body surface in different body regions.
  • the inner surfaces of the hands, the soles of the feet, the knee joints and the entire back area should be emphasized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to an active ingredient product for external human application, comprising an active-ingredient combination of at least one active ingredient from a first active-ingredient group, encompassing Abies alba, Eucalyptus globulus and Glycine soja, and with a further active ingredient from a second active-ingredient group, encompassing camphor, Thymus vulgaris, Mentha piperita and urea.

Description

Wirkstoffpräparat  drug preparation

Die vorliegende Erfindung betrifft ein Wirkstoffpräparat zur äußerenThe present invention relates to a drug preparation for external

Anwendung beim Menschen, umfassend eine Wirkstoff-Kombination aus zumindest einem Wirkstoff einer ersten Wirkstoffgruppe, umfassend Abies Alba, Eucalyptus Globulus und Glycine Soja und einem weiteren Wirkstoff einer zweiten Wirkstoffgruppe, umfassend Camphor, Thymus vulgaris, Menta pipperita und Urea. Use in humans, comprising an active ingredient combination of at least one active ingredient of a first active ingredient group comprising Abies Alba, Eucalyptus Globulus and Glycine soybean and another active ingredient of a second active ingredient group comprising Camphor, Thymus vulgaris, Menta pipperita and Urea.

Des Weiteren betrifft die vorliegende Erfindung die Verwendung des Wirkstoffpräparats zur Herstellung eines zur Behandlung von Menschen geeigneten Präparats, insbesondere zur Behandlung von Diabetes. Furthermore, the present invention relates to the use of the active substance preparation for the preparation of a preparation suitable for the treatment of humans, in particular for the treatment of diabetes.

Die möglichen positiven Effekte einer äußeren Anwendung von pflanzli- chen Extrakten bzw. Wirkstoffpräparaten auf pflanzlicher Basis auf den menschlichen Organismus sind lange bekannt. Dabei lassen sich bestimmten pflanzlichen Extrakten bestimmte Wirkungen zuordnen. The possible positive effects of an external application of plant extracts or plant-based active substance preparations on the human organism have long been known. Certain plant extracts can be assigned specific effects.

Aufgabe der vorliegenden Erfindung ist es, ein Wirstoffpräparat basierend auf pflanzlichen Wirkstoffen bereitzustellen, dass sich insbesondere zur Anwendung bei an Diabetes leidenden Menschen eignet. Zur Lösung dieser Aufgabe weist die vorliegende Erfindung die Merkmale des Anspruchs 1 oder 7 auf. The object of the present invention is to provide an active substance preparation based on herbal active ingredients which is particularly suitable for use in people suffering from diabetes. To solve this problem, the present invention has the features of claim 1 or 7.

In Versuchen mit Kombinationen aus den vorstehend genannten Wirkstoffen, die auch umgangssprachlich bekannt sind unter den Begriffen Weißtannenextrakt (Abies Alba), Eukalyptus Globuli (Eukalyptus Globu- lus), Sojabohnen (Glycine Soja), Camphor, Thymian (Thymus vulgaris), Pfefferminze (Menta pipperita) und Harnstoff (Urea), hat sich gezeigt, dass bereits bei äußerlicher Anwendung positive Effekte feststellbar sind; insbesondere bei unter Diabetes leidenden Menschen. Besonders nachhaltige Effekte, die in einem unmittelbarem Zusammenhang zwischen der äußeren Anwendung der erfindungsgemäßen Wirkstoffkombination an einem unter Diabetes leidenden Menschen und dem Einfluss dieser äußeren Anwendung auf den Blutzuckerspiegel deutlich werden, sind bei einer Ausführung des Wirkstoffpräparats mit einer Wirkstoff-Kombination feststellbar, die Abies Alba, Eucalyptus Globu- lus, Glycine Soja, Abies Alba, Eucalyptus Globulus und Glycine Soja umfasst. In experiments with combinations of the aforementioned active ingredients, which are colloquially known under the terms Weißtannenenextrakt (Abies Alba), Eucalyptus Globuli (Eucalyptus Globulus), soybeans (Glycine soybean), Camphor, Thyme (Thymus vulgaris), Peppermint (Menta pipperita) and urea (urea), it has been shown that positive effects are already detectable on topical application; especially in people suffering from diabetes. Particularly sustainable effects, which become apparent in a direct connection between the external application of the active ingredient combination according to the invention on a person suffering from diabetes and the influence of this external application on the blood sugar level, can be detected in an embodiment of the active substance preparation with a combination of active substances, the Abies Alba , Eucalyptus Globulus, Glycine Soy, Abies Alba, Eucalyptus Globulus and Glycine Soy.

Selbst bei verhältnismäßig geringer Dosierung der Wirkstoffkombination bzw. relativ kleiner, mit der Wirkstoffkombination beaufschlagter Oberfläche des menschlichen Körpers konnte nach Zugabe einer Aminosäure zu der Wirkstoffkombination ein deutlicher Effekt festgestellt werden, da o ffensichtlich die Ergänzung der Wirkstoffkombination mit einer Amino säure eine durch die Amino säure bedingte katalytische Wirkung zeigt. Als einsetzbare Amino säuren haben sich als besonders vorteilhaft herausgestellt, eine oder mehrere Aminosäuren aus einer Gruppe von Amino säuren, die Methionin, Methyl Aspartic Acid und Methyl Glutamic Acid umfasst. Even at relatively low dosage of active ingredient combination or relatively small, acted upon with the drug combination surface of the human body could be found after addition of an amino acid to the drug combination a significant effect, as o obviously the addition of drug combination with an amino acid by the amino acid shows conditional catalytic effect. As usable amino acids have been found to be particularly advantageous, one or more amino acids from a group of amino acids comprising methionine, methyl aspartic acid and methyl glutamic acid.

Um eine einfache Applikation des Wirkstoffpräparats bzw. der in dem Wirkstoffpräparat enthaltenen Wirkstoffkombination zu ermöglichen, ist es vorteilhaft, wenn das Wirkstoffpräparat als Lösungs- und/oder Kon- servierungsmittel einen Alkoho l aufweist, der vorzugsweise aus einer Gruppe von Alkoho len gewählt ist, die Cetyl Alkoho l, Ceteareth-25 , Ceteareth-6 und Stearylalcoho l umfasst. In order to enable a simple application of the active substance preparation or of the active ingredient combination contained in the active substance preparation, it is advantageous if the active substance preparation is used as solution and / or con- Serving agent has an alcohol which is preferably selected from a group of alcohols which comprises cetyl alcohol, ceteareth-25, ceteareth-6 and stearyl alcohol.

Um eine die Anwendung des Wirkstoffpräparats am menschlichen Körper erleichternde, anhaftende Applikation des Wirkstoffpräparats am menschlichen Körper zu ermöglichen, ist es vorteilhaft, wenn das Wirkstoffpräparat auf Basis einer Wasser/Öl-Emulsion hergestellt ist, die ein pflanzliches Verdickungsmittel aufweist. Zum einen wird aufgrund der durch das Verdickungsmittel erhöhten Viskosität die Haftung des Wirk- Stoffpräparats an einer ausgewählten Körperstelle erhöht, zum anderen wird diese Viskositätserhöhung erzielt, ohne dass synthetische Zusatzmittel hinzugegeben werden müssten. In order to facilitate the application of the active substance preparation to the human body, adhesive application of the active substance preparation on the human body, it is advantageous if the active substance preparation is prepared on the basis of a water / oil emulsion having a vegetable thickening agent. On the one hand, due to the viscosity increased by the thickener, the adhesion of the active substance preparation at a selected body site is increased, on the other hand this increase in viscosity is achieved without synthetic additives having to be added.

Als pflanzliche Verdickungsmittel haben sich dabei Hennamehl oder Getreidemehl als besonders vorteilhaft herausgestellt. Zur Erzeilung einer cremig-pastösen Erscheinungsform des Wirkstoffpräparats kann das Wirkstoffpräparat zumindest einen Zusatzstoff aus einer Gruppe von Zusatzstoffen, umfassend Glycerin, Paraffinum Liquidum, Glyceryl Stearate (Wo llwachs) oder auch Dimethycone (Silikon) aufweisen. Diese cremig-pastöse Konsistenz ermöglicht eine entspre- chend langwährende Beaufschlagung ein und derselben Körperstelle mit dem Wirkstoffpräparat, so dass dieses auch ohne Zuhilfenahme von weiteren Trägermaterialien, wie beispielsweise Verbandmaterial, lagefixiert an Ort und Stelle verbleiben kann. Henna meal or cereal flour have proven particularly advantageous as vegetable thickeners. To Erzeilung a creamy pasty appearance of the drug preparation, the drug preparation may comprise at least one additive from a group of additives comprising glycerol, paraffin liquid, glyceryl stearate (Wo llwachs) or dimethycones (silicone). This creamy-pasty consistency allows a correspondingly long-lasting application of one and the same body site to the active substance preparation, so that it can remain fixed in position even without the aid of further carrier materials, for example dressing material.

Ausführungsbeispiel: Als besonders für die Praxis geeignet und vielseitig anwendbar hat sich eine Rezeptur für das Wirkstoffpräparat herausgestellt, die in nachfo lgender Tabelle mit den einzelnen aufgeführten Rezepturbestandteilen dargestellt ist. - Lawsonia Inermis 16,60%Exemplary embodiment: A recipe for the active substance preparation has proved to be particularly suitable for practical use and has versatile applicability, which is shown in the table below with the individual formulation components listed. - Lawsonia Inermis 16.60%

- Glycerin 5% - Glycerin 5%

- Paraffinum Liquidum 5%  - Paraffin Liquidum 5%

- Benzophenone - 4 4%  - Benzophenones - 4 4%

- Glyceryl Stearate 4%  - Glyceryl Stearate 4%

- Cetyl Alkohol 4%  - Cetyl Alcohol 4%

- Ceteareth - 25 2%  - Ceteareth - 25 2%

- Ceteareth - 6 and Stearylalcohol 2%  - Ceteareth - 6 and Stearyl alcohol 2%

- Dimethycone 1%  - Dimethycone 1%

- Abies Alba 1%  - Abies Alba 1%

- Eucalyptus Globulus 1%  - Eucalyptus Globulus 1%

- Glycine Soja 0,5% - Glycine soy 0.5%

- Methylparaben 0,1%Methylparaben 0.1%

- Propylparaben 0,1%- Propylparaben 0.1%

- Isopropylparaben 0,1%- isopropylparaben 0.1%

- Butylparaben 0,1%- butylparaben 0.1%

- Methylchloroisothiazolinone, methyllisothiazolinone 0,1%Methylchloroisothiazolinone, methyllisothiazolinone 0.1%

- Parfüm 0,1%- Perfume 0.1%

- Alcohol 0,1%- Alcohol 0.1%

- Sodium Chloride 0,1%- Sodium Chloride 0.1%

- Methionin 0,1%- Methionine 0.1%

- Potassium Chloride 0,05%- Potassium Chloride 0.05%

- Calcium Chloride 0,05%- Calcium Chloride 0.05%

- Camphor 0,05%- Camphor 0.05%

- Thymus vulgaris 0,05%- Thymus vulgaris 0.05%

- Menta pipperita 0,05%- Menta pipperita 0.05%

- Urea 0,05%- Urea 0.05%

- Methyl Aspartic Acid 0,05%- Methyl Aspartic Acid 0.05%

- Methyl Glutamic Acid 0,05%Methyl glutamic acid 0.05%

- Rest Wasser - rest water

Bei dem explizit hinsichtlich seiner Zusammensetzung gelisteten Aus führungsbeispiel wird als Verdickungsmitte Hennamehl (Lawsonia Inermis) verwendet. Ergänzend zu den bereits vorstehend erläuterten vorteilhaften Wirkstoffen und Wirkstoffkatalysatoren (Amino säuren) kommen bei der beispielhaft ausgewählten Rezeptur zusätzliche Bestandteile zum Einsatz, die wie beispielsweise das Benzophenone-4, das als Lichtschutz wirkt, eine Anwendung des Wirkstoffpräparats auch unter direkter Sonnenbestrahlung, als außerhalb geschlossener Räume, ermöglicht, ohne dass eine negative Beeinflussung der Wirkstoffkombination durch UV-Strahlung zu befürchten wäre. Weiterhin finden sich in der beispielhaften Rezeptur zusätzliche Zuschlagstoffe als Bestandteile, wie beispielsweise Potassium Chlorid (Pottasche) und verschiedene Salze. Henna meal (Lawsonia Inermis) is used as thickening center in the embodiment listed explicitly in terms of its composition. In addition to those already explained above Advantageous active ingredients and active ingredient catalysts (amino acids) are used in the example selected recipe additional ingredients used, such as benzophenone-4, which acts as a sunscreen, an application of the active compound preparation under direct sunlight, as outside closed rooms, allows without A negative influence of the drug combination by UV radiation would be feared. Furthermore, the example formulation contains additional adjuvants as constituents, such as, for example, potassium chloride (potash) and various salts.

Je nach gewünschter Haltbarkeit des Wirkstoffpräparats können diesem auch konservierende Zusätze, wie beispielsweise Propylparaben oder Methylchloroisothiazo linone, hinzugefügt werden. Auch kann sich der ergänzende Zusatz von antiseptisch wirkenden Bestandteilen als vorteilhaft erweisen. Als Füllsto ff bzw. zur Einstellung der gewünschten Depending on the desired shelf life of the active ingredient preparation, preservative additives such as, for example, propylparaben or methylchloroisothiazolinone, may also be added to it. Also, the complementary addition of antiseptic ingredients may prove beneficial. As Füllsto ff or to set the desired

Konzentration des Wirkstoffpräparats besteht der verbleibende Rest der Gesamtmasse des Wirkstoffpräparats im Wesentlichen aus Wasser. Concentration of the drug preparation, the remainder of the total mass of the drug preparation consists essentially of water.

Das erfindungsgemäße Wirksto ffpräparat eignet sich insbesondere im Fall des vorstehend erläuterten Rezepturbeispiels zum Auftragen auf die Körperoberfläche in unterschiedlichen Körperregionen. Insbesondere sind dabei die Innenflächen der Hände, die Fußsohlen, die Kniegelenke sowie der gesamte Rückenbereich hervorzuheben. The Wirksto ffpräparat invention is particularly suitable in the case of the above-described recipe example for application to the body surface in different body regions. In particular, the inner surfaces of the hands, the soles of the feet, the knee joints and the entire back area should be emphasized.

Claims

Patentansprüche claims Wirkstoffpräparat zur äußeren Anwendung beim Menschen, umfassend eine Wirkstoff-Kombination aus zumindest einem Wirkstoff einer ersten Wirkstoffgruppe, umfassend Abies Alba, Eucalyptus Glo- bulus und Glycine Soja, und mit einem weiteren Wirkstoff einer zweiten Wirkstoffgruppe umfassend Camphor, Thymus vulgaris, Menta pipperita und Urea. Active substance preparation for external use in humans, comprising an active ingredient combination of at least one active ingredient of a first active ingredient group comprising Abies Alba, Eucalyptus Globus and Glycine soy, and with another active ingredient of a second active ingredient group comprising Camphor, Thymus vulgaris, Menta pipperita and Urea , Wirkstoffpräparat nach Anspruch 1, Drug preparation according to claim 1, dadurch g e k e nnz e i c hn e t, characterized, dass die Wirkstoff-Kombination Abies Alba, Eucalyptus Globulus, Glycine Soja, Abies Alba, Eucalyptus Globulus und Glycine Soja um- fasst. that the drug combination includes Abies Alba, Eucalyptus Globulus, Glycine Soy, Abies Alba, Eucalyptus Globulus and Glycine Soy. Wirkstoffpräparat nach Anspruch 1 oder 2, Active substance preparation according to claim 1 or 2, dadurch g e k e nnz e i c hn e t, characterized, dass das Wirkstoffpräparat neben der Wirkstoff -Kombination zumindest eine Aminosäure aus einer Gruppe von Aminosäuren, umfassend Methionin, Methyl Aspartic Acid und Methyl Glutamic Acid, aufweist. Wirkstoffpräparat nach einem der vorangehenden Ansprüche, dadurch g e k e nnz e i c hn e t, in that the active substance preparation has, in addition to the active substance combination, at least one amino acid from a group of amino acids comprising methionine, methyl aspartic acid and methyl glutamic acid. Drug preparation according to one of the preceding claims, characterized in that dass das Wirkstoffpräparat als Lösungs- und/oder Konservierungsmittel zumindest einen Alkohol aus einer Gruppe von Alkoholen, umfassend Cetyl Alkohol, Ceteareth-25, Ceteareth-6 und Stearylalcohol, aufweist. in that the active substance preparation as solvent and / or preservative comprises at least one alcohol from a group of alcohols comprising cetyl alcohol, ceteareth-25, ceteareth-6 and stearyl alcohol. Wirkstoffpräparat nach einem der vorangehenden Ansprüche, dadurch g e k e nnz e i c hn e t, Drug preparation according to one of the preceding claims, characterized in that dass das Wirkstoffpräparat auf Basis einer Wasser/Öl-Emulsion hergestellt ist, die ein pflanzliches Verdickungsmittel aufweist. in that the active substance preparation is produced on the basis of a water / oil emulsion which comprises a vegetable thickener. Wirkstoffpräparat nach Anspruch 5, Drug preparation according to claim 5, dadurch g e k e nnz e i c hn e t, characterized, dass das Wirkstoffpräparat zur Erzielung einer cremig-pastösen Konsistenz zumindest einen Zusatzstoff aus einer Gruppe von Zusatzstoffen, umfassend Glycerin, Paraffinum Liquidum, Glyceryl Stearate und Dimethycone, aufweist. in order to obtain a creamy pasty consistency, the active substance preparation comprises at least one additive from a group of additives comprising glycerol, paraffin liquid, glyceryl stearates and dimethycones. Verwendung des Wirkstoffpräparats nach einem oder mehreren der Ansprüche 1 bis 6 zur Herstellung eines zur Behandlung von Menschen geeigneten Präparats, insbesondere zur Behandlung von Diab tes. Use of the active compound preparation according to one or more of claims 1 to 6 for the preparation of a preparation suitable for the treatment of humans, in particular for the treatment of diab tes.
PCT/EP2010/066170 2009-10-28 2010-10-26 Active ingredient product Ceased WO2011051289A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174293A EP2322192A1 (en) 2009-10-28 2009-10-28 Active agent preparation
EP09174293.2 2009-10-28

Publications (1)

Publication Number Publication Date
WO2011051289A1 true WO2011051289A1 (en) 2011-05-05

Family

ID=41718561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/066170 Ceased WO2011051289A1 (en) 2009-10-28 2010-10-26 Active ingredient product

Country Status (2)

Country Link
EP (1) EP2322192A1 (en)
WO (1) WO2011051289A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
JP2001354538A (en) * 2000-06-08 2001-12-25 Noevir Co Ltd Skin care preparation
KR20020025152A (en) * 2002-03-08 2002-04-03 안용준, 김영수 Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism
US20020136788A1 (en) * 2001-03-23 2002-09-26 Quezada Richard S. Therapeutic oil composition
KR20040028481A (en) * 2002-09-30 2004-04-03 주식회사 내츄로바이오텍 Composition for controlling head louse
US20050112153A1 (en) * 2003-11-26 2005-05-26 Wagoner Bruce K. Dermatological composition
US20060073219A1 (en) * 2004-10-04 2006-04-06 Marc Selner Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes
US7329420B1 (en) * 2006-04-06 2008-02-12 Maria Lukacs Herbal remedy system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO116458B1 (en) * 1997-07-28 2001-02-28 Daniela Teodorescu Pharmaceutical composition having antibacterial and antifungal effects

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
JP2001354538A (en) * 2000-06-08 2001-12-25 Noevir Co Ltd Skin care preparation
US20020136788A1 (en) * 2001-03-23 2002-09-26 Quezada Richard S. Therapeutic oil composition
KR20020025152A (en) * 2002-03-08 2002-04-03 안용준, 김영수 Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism
KR20040028481A (en) * 2002-09-30 2004-04-03 주식회사 내츄로바이오텍 Composition for controlling head louse
US20050112153A1 (en) * 2003-11-26 2005-05-26 Wagoner Bruce K. Dermatological composition
US20060073219A1 (en) * 2004-10-04 2006-04-06 Marc Selner Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes
US7329420B1 (en) * 2006-04-06 2008-02-12 Maria Lukacs Herbal remedy system

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200134, Derwent World Patents Index; AN 2001-326411, XP002594883 *
DATABASE WPI Week 200235, Derwent World Patents Index; AN 2002-310729, XP002594929 *
DATABASE WPI Week 200347, Derwent World Patents Index; AN 2003-500918, XP002594930 *
DATABASE WPI Week 200452, Derwent World Patents Index; AN 2004-540909, XP002594931 *

Also Published As

Publication number Publication date
EP2322192A1 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
CN115919733B (en) Cosmetic composition for removing acnes and preparation method thereof
JPH05506851A (en) Methods and products for promoting hair growth and treating skin
EP2029089B1 (en) O/w emulsion for caring for hands
CN114146030B (en) Itching-relieving and relaxing bath lotion and preparation method thereof
KR102165559B1 (en) Cosmetic composition with excellent contribution to improvement
DE19922193B4 (en) Water-soluble concentrate consisting of essential oils microencapsulated in a liposome system, a process for its preparation and its use
CN107496317A (en) A kind of restoration care shampoo of the active component containing American cockroach
CN113425661A (en) Plant composition with cleaning and repairing effects and application thereof
DE202007008601U1 (en) Means for the treatment of hair and use of the agent
JP4501025B2 (en) Skin tick control agent
CN106635563A (en) Weak acid crystal soap for skin health and purification
DE60120744T2 (en) AGAINST FEET TISSUE CONTAINING GARLIC ONIONS
DE60022689T2 (en) PHARMACEUTICAL DISINFECTANTS CONTAINING USNIC ACID AND AN ESSENTIAL OIL
WO2011051289A1 (en) Active ingredient product
DE69705968T2 (en) PREPARATION BASED ON COCONUT OIL AND THEIR USE
DE3316597C1 (en) Gelatinous preparation, and the use thereof as a medicament
JPH0217117A (en) Hair tonic
JP2023153398A (en) Skin external preparation
KR102071600B1 (en) Cream composition manufacturing method for preventing of sensitive-skin and skin-trouble
CN116077382A (en) Composition with moisturizing effect and preparation method and application thereof
RU2660347C1 (en) Cosmetic composition against seborrheic manifestations on the skin
JP6315533B1 (en) Topical skin preparation
CN113599327B (en) Plant composition with functions of shrinking pores and removing blackheads and application thereof
RU2299726C2 (en) Curative-prophylactic anti-infectious labial pomade
KR102569171B1 (en) Hair tone up shampoo composition, Hair tone up shampoo using the same and Manufacturing method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782213

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782213

Country of ref document: EP

Kind code of ref document: A1